PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
9768567-0	1998	Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors.	N,N-dimethyltryptamine	22-44	5-hydroxytryptamine receptor 2A	Homo sapiens	58-70
1828347-2	1991	The affinity of DMT for 5-HT1A sites labeled by [3H]-8-hydroxy-2-(di-n-propylamino)tetralin ([3H]-8-OH-DPAT) was decreased in the presence of 10(-4) M GTP, suggesting agonist activity of DMT at this receptor.	N,N-dimethyltryptamine	187-190	5-hydroxytryptamine receptor 1A	Rattus norvegicus	24-30
8297216-6	1994	Dimethyltryptamine dose dependently elevated blood pressure, heart rate, pupil diameter, and rectal temperature, in addition to elevating blood concentrations of beta-endorphin, corticotropin, cortisol, and prolactin.	N,N-dimethyltryptamine	0-18	proopiomelanocortin	Homo sapiens	162-176
9768567-10	1998	Thus, we conclude that DMT behaves as an agonist at both 5-HT2A and 5-HT2A receptors.	N,N-dimethyltryptamine	23-26	5-hydroxytryptamine receptor 2A	Homo sapiens	57-69
9768567-10	1998	Thus, we conclude that DMT behaves as an agonist at both 5-HT2A and 5-HT2A receptors.	N,N-dimethyltryptamine	23-26	5-hydroxytryptamine receptor 2A	Homo sapiens	59-63
8731519-5	1996	Adrenocorticotropic hormone (ACTH), prolactin, cortisol, and heart rate responses decreased with repeated DMT administration, although blood pressure did not.	N,N-dimethyltryptamine	106-109	proopiomelanocortin	Homo sapiens	0-27
8731519-5	1996	Adrenocorticotropic hormone (ACTH), prolactin, cortisol, and heart rate responses decreased with repeated DMT administration, although blood pressure did not.	N,N-dimethyltryptamine	106-109	proopiomelanocortin	Homo sapiens	29-33
1828347-0	1991	Differential interactions of dimethyltryptamine (DMT) with 5-HT1A and 5-HT2 receptors.	N,N-dimethyltryptamine	29-47	5-hydroxytryptamine receptor 1A	Rattus norvegicus	59-65
1828347-0	1991	Differential interactions of dimethyltryptamine (DMT) with 5-HT1A and 5-HT2 receptors.	N,N-dimethyltryptamine	49-52	5-hydroxytryptamine receptor 1A	Rattus norvegicus	59-65
1828347-1	1991	The interactions of the indolealkylamine N,N-dimethyltryptamine (DMT) with 5-hydroxytryptamine1A (5-HT1A) and 5-HT2 receptors in rat brain were analyzed using radioligand binding techniques and biochemical functional assays.	N,N-dimethyltryptamine	41-63	5-hydroxytryptamine receptor 1A	Rattus norvegicus	75-96
1828347-1	1991	The interactions of the indolealkylamine N,N-dimethyltryptamine (DMT) with 5-hydroxytryptamine1A (5-HT1A) and 5-HT2 receptors in rat brain were analyzed using radioligand binding techniques and biochemical functional assays.	N,N-dimethyltryptamine	41-63	5-hydroxytryptamine receptor 1A	Rattus norvegicus	98-104
1828347-1	1991	The interactions of the indolealkylamine N,N-dimethyltryptamine (DMT) with 5-hydroxytryptamine1A (5-HT1A) and 5-HT2 receptors in rat brain were analyzed using radioligand binding techniques and biochemical functional assays.	N,N-dimethyltryptamine	65-68	5-hydroxytryptamine receptor 1A	Rattus norvegicus	75-96
1828347-1	1991	The interactions of the indolealkylamine N,N-dimethyltryptamine (DMT) with 5-hydroxytryptamine1A (5-HT1A) and 5-HT2 receptors in rat brain were analyzed using radioligand binding techniques and biochemical functional assays.	N,N-dimethyltryptamine	65-68	5-hydroxytryptamine receptor 1A	Rattus norvegicus	98-104
1828347-2	1991	The affinity of DMT for 5-HT1A sites labeled by [3H]-8-hydroxy-2-(di-n-propylamino)tetralin ([3H]-8-OH-DPAT) was decreased in the presence of 10(-4) M GTP, suggesting agonist activity of DMT at this receptor.	N,N-dimethyltryptamine	16-19	5-hydroxytryptamine receptor 1A	Rattus norvegicus	24-30
1828347-3	1991	Adenylate cyclase studies in rat hippocampi showed that DMT inhibited forskolin-stimulated cyclase activity, a 5-HT1A agonist effect.	N,N-dimethyltryptamine	56-59	5-hydroxytryptamine receptor 1A	Rattus norvegicus	111-117
34649091-0	2021	D-MT prompts the anti-tumor effect of oxaliplatin by inhibiting IDO expression in a mouse model of colon cancer.	N,N-dimethyltryptamine	0-4	indoleamine 2,3-dioxygenase 1	Mus musculus	64-67
33814892-3	2021	Recent Findings: Observational data support the safety of injectable DMTs (glatiramer acetate, interferon-beta) for use in pregnancy, while some oral DMTs might be associated with fetal risk.	N,N-dimethyltryptamine	69-73	interferon beta 1	Homo sapiens	95-110
34948383-2	2021	Collagen IV fragments were obtained by using DMT/NMM/TosO- as a coupling reagent.	N,N-dimethyltryptamine	45-48	Fc mu receptor	Homo sapiens	53-57
34649091-4	2021	Herein, an IDO inhibitor, D-MT (indoximod, 1-Methyl-D-tryptophan), was combined with oxaliplatin to treat colon cancer in mice.	N,N-dimethyltryptamine	26-30	indoleamine 2,3-dioxygenase 1	Mus musculus	11-14
34603053-1	2021	Background: Serotonergic psychedelics (SPs) like LSD, psilocybin, DMT, and mescaline are a heterogeneous group of substances that share agonism at 5-HT2a receptors.	N,N-dimethyltryptamine	66-69	5-hydroxytryptamine receptor 2A	Homo sapiens	147-153
34587977-8	2021	Knockdown of INMT or treatment with INMT inhibitor N,N-dimethyltryptamine (DMT) significantly suppressed CRPC development.	N,N-dimethyltryptamine	51-73	indolethylamine N-methyltransferase	Mus musculus	36-40
34587977-8	2021	Knockdown of INMT or treatment with INMT inhibitor N,N-dimethyltryptamine (DMT) significantly suppressed CRPC development.	N,N-dimethyltryptamine	75-78	indolethylamine N-methyltransferase	Mus musculus	13-17
34587977-8	2021	Knockdown of INMT or treatment with INMT inhibitor N,N-dimethyltryptamine (DMT) significantly suppressed CRPC development.	N,N-dimethyltryptamine	75-78	indolethylamine N-methyltransferase	Mus musculus	36-40
35253069-2	2022	The serotonin 5-HT2A receptor agonist N,N-dimethyltryptamine (DMT) is the main psychoactive component of ayahuasca, suggesting that its therapeutic effects may be mediated by 5-HT2A receptors.	N,N-dimethyltryptamine	38-60	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	175-181
34247104-13	2021	The reduction of occludin after 12 months on DMTs might reflect repair of these barriers upon treatment.	N,N-dimethyltryptamine	45-49	occludin	Homo sapiens	17-25
35253069-2	2022	The serotonin 5-HT2A receptor agonist N,N-dimethyltryptamine (DMT) is the main psychoactive component of ayahuasca, suggesting that its therapeutic effects may be mediated by 5-HT2A receptors.	N,N-dimethyltryptamine	62-65	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	175-181
35625734-3	2022	To inhibit its rapid breakdown by monoamine-oxidase A (MAO-A) enzyme, DMT was co-administered with harmaline, a beta-carboline in the Amazonian Ayahuasca brew.	N,N-dimethyltryptamine	70-73	monoamine oxidase A	Rattus norvegicus	34-53
35625734-3	2022	To inhibit its rapid breakdown by monoamine-oxidase A (MAO-A) enzyme, DMT was co-administered with harmaline, a beta-carboline in the Amazonian Ayahuasca brew.	N,N-dimethyltryptamine	70-73	monoamine oxidase A	Rattus norvegicus	55-60
35625734-8	2022	Based on our experiments, DMT and harmaline exert opposite effects on important ocular proteins such as PARP1, NFkappaB, MMP9, or HSP70, each having a critical role in a different mechanism of eye-ischemia-related pathologies, e.g., cell death, inflammation, tissue destruction, and oxidative stress.	N,N-dimethyltryptamine	26-29	poly (ADP-ribose) polymerase 1	Rattus norvegicus	104-109
35625734-8	2022	Based on our experiments, DMT and harmaline exert opposite effects on important ocular proteins such as PARP1, NFkappaB, MMP9, or HSP70, each having a critical role in a different mechanism of eye-ischemia-related pathologies, e.g., cell death, inflammation, tissue destruction, and oxidative stress.	N,N-dimethyltryptamine	26-29	matrix metallopeptidase 9	Rattus norvegicus	121-125
35625734-8	2022	Based on our experiments, DMT and harmaline exert opposite effects on important ocular proteins such as PARP1, NFkappaB, MMP9, or HSP70, each having a critical role in a different mechanism of eye-ischemia-related pathologies, e.g., cell death, inflammation, tissue destruction, and oxidative stress.	N,N-dimethyltryptamine	26-29	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	130-135
35349196-0	2022	Enlightening the "Spirit Molecule": Photomodulation of the 5-HT2A Receptor by a Light-Controllable N,N-Dimethyltryptamine Derivative.	N,N-dimethyltryptamine	99-121	5-hydroxytryptamine receptor 2A	Homo sapiens	59-74
3867833-8	1985	N,N-dimethyltryptamine showed a clear dose-response relationship in the stimulation of the release of prolactin.	N,N-dimethyltryptamine	0-22	prolactin	Rattus norvegicus	102-111
3006089-5	1986	Several mu opioid agonists, antagonists, and synthetic enkephalin analogs interacted with DMT and LSD.	N,N-dimethyltryptamine	90-93	proenkephalin	Rattus norvegicus	55-65
148665-2	1978	The increase in plasma PRL produced by N,N-DMT, psilocybin, and bufotenin was inhibited by methysergide, a serotonin receptor blocker.	N,N-dimethyltryptamine	39-46	prolactin	Rattus norvegicus	23-26
4041865-5	1985	5-HT, bufotenine, N,N-dimethyltryptamine (DMT) and quipazine were only slightly more potent at the 5-HT1A binding site.	N,N-dimethyltryptamine	18-40	5-hydroxytryptamine receptor 1A	Bos taurus	99-105
4041865-5	1985	5-HT, bufotenine, N,N-dimethyltryptamine (DMT) and quipazine were only slightly more potent at the 5-HT1A binding site.	N,N-dimethyltryptamine	42-45	5-hydroxytryptamine receptor 1A	Bos taurus	99-105
510375-1	1979	Repeated administration of 5-methoxy-N,N-dimethyltryptamine (5MeODMT, 5 mg/kg, a serotonin agonist, every 3 h for a total of 4 injections) potentiated its prolactin (PRL)-releasing effect and that of two other serotonin agonists, quipazine and N,N-dimethyltryptamine.	N,N-dimethyltryptamine	37-59	prolactin	Rattus norvegicus	155-164
510375-1	1979	Repeated administration of 5-methoxy-N,N-dimethyltryptamine (5MeODMT, 5 mg/kg, a serotonin agonist, every 3 h for a total of 4 injections) potentiated its prolactin (PRL)-releasing effect and that of two other serotonin agonists, quipazine and N,N-dimethyltryptamine.	N,N-dimethyltryptamine	37-59	prolactin	Rattus norvegicus	166-169
148665-3	1978	Parachlorophenylalanine (PCPA), an inhibitor of serotonin synthesis, significantly potentiated the increase in PRL produced by N,N-DMT, and psilocybin.	N,N-dimethyltryptamine	127-134	prolactin	Rattus norvegicus	111-114
148665-4	1978	Parachloroamphetamine, a relatively selective toxin for serotonin neurons, also stimulated the increase in PRL produced by N,N-DMT.	N,N-dimethyltryptamine	123-130	prolactin	Rattus norvegicus	107-110
8818-1	1976	Desmethylperazine (norperazine) and desmethylprochlorperazine (norprochlorperazine), like nor1- and nor2chlorpromazine, are excellent substrates for indolethylamine N-methyltransferase (NMT) and also inhibit the formation of dimethyltryptamine (DMT) from N-methyl-tryptamine (NMT).	N,N-dimethyltryptamine	225-243	indolethylamine N-methyltransferase	Oryctolagus cuniculus	149-184
8818-1	1976	Desmethylperazine (norperazine) and desmethylprochlorperazine (norprochlorperazine), like nor1- and nor2chlorpromazine, are excellent substrates for indolethylamine N-methyltransferase (NMT) and also inhibit the formation of dimethyltryptamine (DMT) from N-methyl-tryptamine (NMT).	N,N-dimethyltryptamine	245-248	indolethylamine N-methyltransferase	Oryctolagus cuniculus	149-184
32902268-5	2020	Combination of beta3hArg and Dmt led to peptide 7, a MOR agonist, showing the highest NTS2 affinity described to date (Ki = 3 pM) and good NTS1 affinity (Ki = 4 nM), providing a >1300-fold NTS2 selectivity.	N,N-dimethyltryptamine	29-32	opioid receptor, mu 1	Mus musculus	53-56
34023338-0	2021	N,N-Dimethyltryptamine attenuates spreading depolarization and restrains neurodegeneration by sigma-1 receptor activation in the ischemic rat brain.	N,N-dimethyltryptamine	0-22	sigma non-opioid intracellular receptor 1	Rattus norvegicus	94-110
33215182-0	2020	Quantum chemical (QM:MM) investigation of the mechanism of enzymatic reaction of tryptamine and N,N-dimethyltryptamine with monoamine oxidase A.	N,N-dimethyltryptamine	96-118	monoamine oxidase A	Homo sapiens	124-143
32902268-5	2020	Combination of beta3hArg and Dmt led to peptide 7, a MOR agonist, showing the highest NTS2 affinity described to date (Ki = 3 pM) and good NTS1 affinity (Ki = 4 nM), providing a >1300-fold NTS2 selectivity.	N,N-dimethyltryptamine	29-32	nuclear encoded tRNA selenocysteine 2 (anticodon TCA)	Mus musculus	86-90
32902268-5	2020	Combination of beta3hArg and Dmt led to peptide 7, a MOR agonist, showing the highest NTS2 affinity described to date (Ki = 3 pM) and good NTS1 affinity (Ki = 4 nM), providing a >1300-fold NTS2 selectivity.	N,N-dimethyltryptamine	29-32	neurotensin	Mus musculus	139-143
32902268-5	2020	Combination of beta3hArg and Dmt led to peptide 7, a MOR agonist, showing the highest NTS2 affinity described to date (Ki = 3 pM) and good NTS1 affinity (Ki = 4 nM), providing a >1300-fold NTS2 selectivity.	N,N-dimethyltryptamine	29-32	nuclear encoded tRNA selenocysteine 2 (anticodon TCA)	Mus musculus	189-193
33117374-7	2020	Higher levels of IFN-gamma, IL-2, TNF-alpha, and IL-17A secreted by splenocytes were related with a more powerful and durable protection induced by CMFO/DMT through a putative synergistic effect of both MPLA and TDB via binding to TLR4 and Mincle.	N,N-dimethyltryptamine	153-156	interferon gamma	Mus musculus	17-26
33117374-7	2020	Higher levels of IFN-gamma, IL-2, TNF-alpha, and IL-17A secreted by splenocytes were related with a more powerful and durable protection induced by CMFO/DMT through a putative synergistic effect of both MPLA and TDB via binding to TLR4 and Mincle.	N,N-dimethyltryptamine	153-156	interleukin 2	Mus musculus	28-32
33117374-7	2020	Higher levels of IFN-gamma, IL-2, TNF-alpha, and IL-17A secreted by splenocytes were related with a more powerful and durable protection induced by CMFO/DMT through a putative synergistic effect of both MPLA and TDB via binding to TLR4 and Mincle.	N,N-dimethyltryptamine	153-156	tumor necrosis factor	Mus musculus	34-43
33117374-7	2020	Higher levels of IFN-gamma, IL-2, TNF-alpha, and IL-17A secreted by splenocytes were related with a more powerful and durable protection induced by CMFO/DMT through a putative synergistic effect of both MPLA and TDB via binding to TLR4 and Mincle.	N,N-dimethyltryptamine	153-156	interleukin 17A	Mus musculus	49-55
33117374-7	2020	Higher levels of IFN-gamma, IL-2, TNF-alpha, and IL-17A secreted by splenocytes were related with a more powerful and durable protection induced by CMFO/DMT through a putative synergistic effect of both MPLA and TDB via binding to TLR4 and Mincle.	N,N-dimethyltryptamine	153-156	toll-like receptor 4	Mus musculus	231-235
32989216-5	2020	Interestingly, the neurogenic effect of DMT appears to involve signaling via sigma-1 receptor (S1R) activation since S1R antagonist blocked the neurogenic effect.	N,N-dimethyltryptamine	40-43	sigma non-opioid intracellular receptor 1	Mus musculus	77-93
32989216-5	2020	Interestingly, the neurogenic effect of DMT appears to involve signaling via sigma-1 receptor (S1R) activation since S1R antagonist blocked the neurogenic effect.	N,N-dimethyltryptamine	40-43	sigma non-opioid intracellular receptor 1	Mus musculus	95-98
32989216-5	2020	Interestingly, the neurogenic effect of DMT appears to involve signaling via sigma-1 receptor (S1R) activation since S1R antagonist blocked the neurogenic effect.	N,N-dimethyltryptamine	40-43	sigma non-opioid intracellular receptor 1	Mus musculus	117-120
31249368-1	2019	N,N-dimethyltryptamine (DMT), a psychedelic compound identified endogenously in mammals, is biosynthesized by aromatic-L-amino acid decarboxylase (AADC) and indolethylamine-N-methyltransferase (INMT).	N,N-dimethyltryptamine	0-22	dopa decarboxylase	Rattus norvegicus	110-145
32345112-11	2020	CONCLUSION: N,N-dimethyltryptamine-occasioned entity encounter experiences have many similarities to non-drug entity encounter experiences such as those described in religious, alien abduction, and near-death contexts.	N,N-dimethyltryptamine	12-34	COP9 signalosome subunit 2	Homo sapiens	177-182
32067950-1	2020	BACKGROUND AND PURPOSE: N,N-dimethyltryptamine (DMT) is an endogenous ligand of the Sigma 1 receptor (Sig-1R) with documented in vitro cytoprotective properties against hypoxia.	N,N-dimethyltryptamine	24-46	sigma non-opioid intracellular receptor 1	Rattus norvegicus	84-100
32067950-1	2020	BACKGROUND AND PURPOSE: N,N-dimethyltryptamine (DMT) is an endogenous ligand of the Sigma 1 receptor (Sig-1R) with documented in vitro cytoprotective properties against hypoxia.	N,N-dimethyltryptamine	24-46	sigma non-opioid intracellular receptor 1	Rattus norvegicus	102-108
32067950-1	2020	BACKGROUND AND PURPOSE: N,N-dimethyltryptamine (DMT) is an endogenous ligand of the Sigma 1 receptor (Sig-1R) with documented in vitro cytoprotective properties against hypoxia.	N,N-dimethyltryptamine	48-51	sigma non-opioid intracellular receptor 1	Rattus norvegicus	84-100
32067950-1	2020	BACKGROUND AND PURPOSE: N,N-dimethyltryptamine (DMT) is an endogenous ligand of the Sigma 1 receptor (Sig-1R) with documented in vitro cytoprotective properties against hypoxia.	N,N-dimethyltryptamine	48-51	sigma non-opioid intracellular receptor 1	Rattus norvegicus	102-108
32067950-13	2020	Sig-1R was expressed both in neurons and in microglia in the peri-infarct cortex, and the DMT induced change in the lesion volume was hindered by BD1063.	N,N-dimethyltryptamine	90-93	sigma non-opioid intracellular receptor 1	Rattus norvegicus	0-6
32067950-15	2020	CONCLUSION: Our results indicate a Sig-1R dependent reduction of the ischemic brain injury following exogenous DMT administration in rats, presumably through a combined anti-apoptotic, pro-neurotrophic and anti-inflammatory treatment effect.	N,N-dimethyltryptamine	111-114	sigma non-opioid intracellular receptor 1	Rattus norvegicus	35-41
32772067-3	2020	Its biological activity results from the content of N,N-dimethyltryptamine (DMT), acting mainly as a non-selective agonist of serotonin receptors and beta-carboline alkaloids, which are strong and short-acting monoamine oxidase type A(MAOI-A) inhibitors.	N,N-dimethyltryptamine	52-74	monoamine oxidase A	Homo sapiens	210-234
32772067-3	2020	Its biological activity results from the content of N,N-dimethyltryptamine (DMT), acting mainly as a non-selective agonist of serotonin receptors and beta-carboline alkaloids, which are strong and short-acting monoamine oxidase type A(MAOI-A) inhibitors.	N,N-dimethyltryptamine	76-79	monoamine oxidase A	Homo sapiens	210-234
31249368-1	2019	N,N-dimethyltryptamine (DMT), a psychedelic compound identified endogenously in mammals, is biosynthesized by aromatic-L-amino acid decarboxylase (AADC) and indolethylamine-N-methyltransferase (INMT).	N,N-dimethyltryptamine	0-22	dopa decarboxylase	Rattus norvegicus	147-151
31249368-1	2019	N,N-dimethyltryptamine (DMT), a psychedelic compound identified endogenously in mammals, is biosynthesized by aromatic-L-amino acid decarboxylase (AADC) and indolethylamine-N-methyltransferase (INMT).	N,N-dimethyltryptamine	0-22	indolethylamine N-methyltransferase	Rattus norvegicus	157-192
31249368-1	2019	N,N-dimethyltryptamine (DMT), a psychedelic compound identified endogenously in mammals, is biosynthesized by aromatic-L-amino acid decarboxylase (AADC) and indolethylamine-N-methyltransferase (INMT).	N,N-dimethyltryptamine	0-22	indolethylamine N-methyltransferase	Rattus norvegicus	194-198
31249368-1	2019	N,N-dimethyltryptamine (DMT), a psychedelic compound identified endogenously in mammals, is biosynthesized by aromatic-L-amino acid decarboxylase (AADC) and indolethylamine-N-methyltransferase (INMT).	N,N-dimethyltryptamine	24-27	dopa decarboxylase	Rattus norvegicus	110-145
31249368-1	2019	N,N-dimethyltryptamine (DMT), a psychedelic compound identified endogenously in mammals, is biosynthesized by aromatic-L-amino acid decarboxylase (AADC) and indolethylamine-N-methyltransferase (INMT).	N,N-dimethyltryptamine	24-27	dopa decarboxylase	Rattus norvegicus	147-151
31249368-1	2019	N,N-dimethyltryptamine (DMT), a psychedelic compound identified endogenously in mammals, is biosynthesized by aromatic-L-amino acid decarboxylase (AADC) and indolethylamine-N-methyltransferase (INMT).	N,N-dimethyltryptamine	24-27	indolethylamine N-methyltransferase	Rattus norvegicus	157-192
31249368-1	2019	N,N-dimethyltryptamine (DMT), a psychedelic compound identified endogenously in mammals, is biosynthesized by aromatic-L-amino acid decarboxylase (AADC) and indolethylamine-N-methyltransferase (INMT).	N,N-dimethyltryptamine	24-27	indolethylamine N-methyltransferase	Rattus norvegicus	194-198
29740267-0	2018	Indolethylamine-N-methyltransferase Polymorphisms: Genetic and Biochemical Approaches for Study of Endogenous N,N,-dimethyltryptamine.	N,N-dimethyltryptamine	110-133	indolethylamine N-methyltransferase	Homo sapiens	0-35
29740267-2	2018	Studies have identified DMT and analogous compounds (e.g., 5-hydroxy-DMT, 5-methoxy-DMT) alongside of an enzyme capable of synthesizing DMT endogenously from tryptamine, indolethylamine-N-methyltransferase (INMT), in human and several other mammalian tissues.	N,N-dimethyltryptamine	24-27	indolethylamine N-methyltransferase	Homo sapiens	170-205
29740267-2	2018	Studies have identified DMT and analogous compounds (e.g., 5-hydroxy-DMT, 5-methoxy-DMT) alongside of an enzyme capable of synthesizing DMT endogenously from tryptamine, indolethylamine-N-methyltransferase (INMT), in human and several other mammalian tissues.	N,N-dimethyltryptamine	24-27	indolethylamine N-methyltransferase	Homo sapiens	207-211
29740267-2	2018	Studies have identified DMT and analogous compounds (e.g., 5-hydroxy-DMT, 5-methoxy-DMT) alongside of an enzyme capable of synthesizing DMT endogenously from tryptamine, indolethylamine-N-methyltransferase (INMT), in human and several other mammalian tissues.	N,N-dimethyltryptamine	69-72	indolethylamine N-methyltransferase	Homo sapiens	170-205
29740267-2	2018	Studies have identified DMT and analogous compounds (e.g., 5-hydroxy-DMT, 5-methoxy-DMT) alongside of an enzyme capable of synthesizing DMT endogenously from tryptamine, indolethylamine-N-methyltransferase (INMT), in human and several other mammalian tissues.	N,N-dimethyltryptamine	69-72	indolethylamine N-methyltransferase	Homo sapiens	207-211
27216487-5	2016	Binding affinity to the 5-HT2A receptor was lower for all of the tryptamines, including psilocin and DMT, compared with LSD and correlated with the reported psychoactive doses in humans.	N,N-dimethyltryptamine	101-104	5-hydroxytryptamine receptor 2A	Homo sapiens	24-39
29674970-2	2018	N,N-Dimethyltryptamine (DMT, one of the alkaloids in Ayahuasca) activates sigma 1 receptor (SIGMAR1) and others.	N,N-dimethyltryptamine	0-22	sigma non-opioid intracellular receptor 1	Homo sapiens	92-99
29674970-2	2018	N,N-Dimethyltryptamine (DMT, one of the alkaloids in Ayahuasca) activates sigma 1 receptor (SIGMAR1) and others.	N,N-dimethyltryptamine	24-27	sigma non-opioid intracellular receptor 1	Homo sapiens	92-99
28554311-15	2018	Dimethyl tryptamine (DMT) and neuroactive steroids are endogenous ligands that activate Sig-1R.	N,N-dimethyltryptamine	0-19	sigma non-opioid intracellular receptor 1	Homo sapiens	88-94
28554311-15	2018	Dimethyl tryptamine (DMT) and neuroactive steroids are endogenous ligands that activate Sig-1R.	N,N-dimethyltryptamine	21-24	sigma non-opioid intracellular receptor 1	Homo sapiens	88-94
28525587-1	2017	Background: Ayahuasca is a plant tea containing the psychedelic 5-HT2A agonist N,N-dimethyltryptamine and harmala monoamine-oxidase inhibitors.	N,N-dimethyltryptamine	79-101	5-hydroxytryptamine receptor 2A	Homo sapiens	64-70
27683542-0	2016	The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells.	N,N-dimethyltryptamine	44-66	sigma non-opioid intracellular receptor 1	Homo sapiens	128-144
27683542-0	2016	The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells.	N,N-dimethyltryptamine	68-71	sigma non-opioid intracellular receptor 1	Homo sapiens	128-144
27683542-9	2016	Furthermore, this phenomenon is associated with the decreased expression and function of the alpha subunit of the hypoxia-inducible factor 1 (HIF-1) suggesting that DMT-mediated Sig-1R activation may alleviate hypoxia-induced cellular stress and increase survival in a HIF-1-independent manner.	N,N-dimethyltryptamine	165-168	hypoxia inducible factor 1 subunit alpha	Homo sapiens	142-147
27683542-9	2016	Furthermore, this phenomenon is associated with the decreased expression and function of the alpha subunit of the hypoxia-inducible factor 1 (HIF-1) suggesting that DMT-mediated Sig-1R activation may alleviate hypoxia-induced cellular stress and increase survival in a HIF-1-independent manner.	N,N-dimethyltryptamine	165-168	sigma non-opioid intracellular receptor 1	Homo sapiens	178-184
27683542-9	2016	Furthermore, this phenomenon is associated with the decreased expression and function of the alpha subunit of the hypoxia-inducible factor 1 (HIF-1) suggesting that DMT-mediated Sig-1R activation may alleviate hypoxia-induced cellular stress and increase survival in a HIF-1-independent manner.	N,N-dimethyltryptamine	165-168	hypoxia inducible factor 1 subunit alpha	Homo sapiens	269-274
28315276-8	2017	The S1R colocalizes in C-terminals with Indole(ethyl)amine-N-methyl transferase (INMT ), the enzyme that produces the S1R agonist , N,N"- dimethyltryptamine (DMT).	N,N-dimethyltryptamine	132-156	sigma non-opioid intracellular receptor 1	Mus musculus	4-7
28315276-8	2017	The S1R colocalizes in C-terminals with Indole(ethyl)amine-N-methyl transferase (INMT ), the enzyme that produces the S1R agonist , N,N"- dimethyltryptamine (DMT).	N,N-dimethyltryptamine	132-156	indolethylamine N-methyltransferase	Mus musculus	81-85
28315276-8	2017	The S1R colocalizes in C-terminals with Indole(ethyl)amine-N-methyl transferase (INMT ), the enzyme that produces the S1R agonist , N,N"- dimethyltryptamine (DMT).	N,N-dimethyltryptamine	132-156	sigma non-opioid intracellular receptor 1	Mus musculus	118-121
28315276-8	2017	The S1R colocalizes in C-terminals with Indole(ethyl)amine-N-methyl transferase (INMT ), the enzyme that produces the S1R agonist , N,N"- dimethyltryptamine (DMT).	N,N-dimethyltryptamine	158-161	sigma non-opioid intracellular receptor 1	Mus musculus	4-7
28315276-8	2017	The S1R colocalizes in C-terminals with Indole(ethyl)amine-N-methyl transferase (INMT ), the enzyme that produces the S1R agonist , N,N"- dimethyltryptamine (DMT).	N,N-dimethyltryptamine	158-161	indolethylamine N-methyltransferase	Mus musculus	81-85
28315276-8	2017	The S1R colocalizes in C-terminals with Indole(ethyl)amine-N-methyl transferase (INMT ), the enzyme that produces the S1R agonist , N,N"- dimethyltryptamine (DMT).	N,N-dimethyltryptamine	158-161	sigma non-opioid intracellular receptor 1	Mus musculus	118-121
28315276-9	2017	INMT methylation can additionally neutralize endogenous toxic sulfur and selenium derivatives thus providing functional synergism with DMT to reduce oxidative stress in motor neurons .	N,N-dimethyltryptamine	135-138	indolethylamine N-methyltransferase	Mus musculus	0-4
27435062-2	2016	The tea contains the psychedelic 5-HT2A receptor agonist N,N-dimethyltryptamine (DMT), plus beta-carboline alkaloids with monoamine oxidase-inhibiting properties.	N,N-dimethyltryptamine	57-79	5-hydroxytryptamine receptor 2A	Homo sapiens	33-48
27216487-6	2016	Several tryptamines, including psilocin, DMT, DiPT, 4-OH-DiPT, and 4-OH-MET, interacted with the serotonin transporter and partially the norepinephrine transporter, similar to 3,4-methylenedioxymethamphetamine but in contrast to LSD and mescaline.	N,N-dimethyltryptamine	41-44	solute carrier family 6 member 4	Homo sapiens	97-118
26599973-3	2016	All tested TDNPS with the exception of DMT inhibited CYP2D6 activity with IC50 values below 100muM.	N,N-dimethyltryptamine	39-42	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	53-59
26973523-7	2016	A growing number of studies indicate that the psychotherapeutic potential of ayahuasca is based mostly on the strong serotonergic effects, whereas the sigma-1 receptor (Sig-1R) agonist effect of its active ingredient dimethyltryptamine raises the possibility that the ethnomedical observations on the diversity of treated conditions can be scientifically verified.	N,N-dimethyltryptamine	217-235	sigma non-opioid intracellular receptor 1	Homo sapiens	151-167
26973523-7	2016	A growing number of studies indicate that the psychotherapeutic potential of ayahuasca is based mostly on the strong serotonergic effects, whereas the sigma-1 receptor (Sig-1R) agonist effect of its active ingredient dimethyltryptamine raises the possibility that the ethnomedical observations on the diversity of treated conditions can be scientifically verified.	N,N-dimethyltryptamine	217-235	sigma non-opioid intracellular receptor 1	Homo sapiens	169-175
26612618-3	2016	The tea contains the psychedelic 5-HT2A receptor agonist N,N-dimethyltryptamine (DMT), plus beta-carboline alkaloids with monoamine-oxidase-inhibiting properties.	N,N-dimethyltryptamine	57-79	5-hydroxytryptamine receptor 2A	Homo sapiens	33-48
25069786-1	2015	N,N-dimethyltryptamine (DMT) is a widely distributed plant alkaloid that displays partial agonist activity at the 5-HT2A receptor and induces intense psychedelic effects in humans when administered parenterally.	N,N-dimethyltryptamine	0-22	5-hydroxytryptamine receptor 2A	Homo sapiens	114-129
25069786-1	2015	N,N-dimethyltryptamine (DMT) is a widely distributed plant alkaloid that displays partial agonist activity at the 5-HT2A receptor and induces intense psychedelic effects in humans when administered parenterally.	N,N-dimethyltryptamine	24-27	5-hydroxytryptamine receptor 2A	Homo sapiens	114-129
24508833-6	2014	Furthermore, when we added DMT to the cell culture, we found hydroxy-DMT (OH-DMT) and indole acetic acid (IAA) in the cell supernatant at 24 h. We found that SK-Mel-147 cells expressed mRNA for myeloperoxidase (MPO) and also had peroxidase activity.	N,N-dimethyltryptamine	27-30	myeloperoxidase	Homo sapiens	194-209
25171370-5	2014	The T-cell activating capacity of moDCs was also inhibited, and dimethyltryptamines used in combination with E. coli or influenza virus as stimulators decreased the differentiation of moDC-induced Th1 and Th17 inflammatory effector T-cells in a sigmar-1 specific manner as confirmed by gene silencing.	N,N-dimethyltryptamine	64-83	sigma non-opioid intracellular receptor 1	Homo sapiens	245-253
25171370-6	2014	Here we demonstrate for the first time the immunomodulatory potential of NN-DMT and 5-MeO-DMT on human moDC functions via sigmar-1 that could be harnessed for the pharmacological treatment of autoimmune diseases and chronic inflammatory conditions of the CNS or peripheral tissues.	N,N-dimethyltryptamine	73-79	sigma non-opioid intracellular receptor 1	Homo sapiens	122-130
25820842-7	2015	They received a placebo or a dose of ayahuasca, a psychedelic preparation containing the serotonergic 5-HT2A agonist N,N-dimethyltryptamine.	N,N-dimethyltryptamine	117-139	5-hydroxytryptamine receptor 2A	Homo sapiens	102-108
24730580-0	2014	Noncompetitive inhibition of indolethylamine-N-methyltransferase by N,N-dimethyltryptamine and N,N-dimethylaminopropyltryptamine.	N,N-dimethyltryptamine	68-90	indolethylamine N-methyltransferase	Homo sapiens	29-64
24730580-1	2014	Indolethylamine-N-methyltransferase (INMT) is a Class 1 transmethylation enzyme known for its production of N,N-dimethyltryptamine (DMT), a hallucinogen with affinity for various serotonergic, adrenergic, histaminergic, dopaminergic, and sigma-1 receptors.	N,N-dimethyltryptamine	108-130	indolethylamine N-methyltransferase	Homo sapiens	0-35
24730580-1	2014	Indolethylamine-N-methyltransferase (INMT) is a Class 1 transmethylation enzyme known for its production of N,N-dimethyltryptamine (DMT), a hallucinogen with affinity for various serotonergic, adrenergic, histaminergic, dopaminergic, and sigma-1 receptors.	N,N-dimethyltryptamine	108-130	indolethylamine N-methyltransferase	Homo sapiens	37-41
24730580-1	2014	Indolethylamine-N-methyltransferase (INMT) is a Class 1 transmethylation enzyme known for its production of N,N-dimethyltryptamine (DMT), a hallucinogen with affinity for various serotonergic, adrenergic, histaminergic, dopaminergic, and sigma-1 receptors.	N,N-dimethyltryptamine	132-135	indolethylamine N-methyltransferase	Homo sapiens	0-35
24730580-1	2014	Indolethylamine-N-methyltransferase (INMT) is a Class 1 transmethylation enzyme known for its production of N,N-dimethyltryptamine (DMT), a hallucinogen with affinity for various serotonergic, adrenergic, histaminergic, dopaminergic, and sigma-1 receptors.	N,N-dimethyltryptamine	132-135	indolethylamine N-methyltransferase	Homo sapiens	37-41
24730580-2	2014	DMT is produced via the action of INMT on the endogenous substrates tryptamine and S-adenosyl-l-methionine (SAM).	N,N-dimethyltryptamine	0-3	indolethylamine N-methyltransferase	Homo sapiens	34-38
24508833-6	2014	Furthermore, when we added DMT to the cell culture, we found hydroxy-DMT (OH-DMT) and indole acetic acid (IAA) in the cell supernatant at 24 h. We found that SK-Mel-147 cells expressed mRNA for myeloperoxidase (MPO) and also had peroxidase activity.	N,N-dimethyltryptamine	27-30	myeloperoxidase	Homo sapiens	211-214
24508833-8	2014	DMT oxidation by horseradish peroxidase, H2O2 and MPO from PMA-activated neutrophils produced DMFK, N,N-dimethyl-kynuramine (DMK) and OH-DMT.	N,N-dimethyltryptamine	0-3	myeloperoxidase	Homo sapiens	50-53
23754498-7	2013	We conclude that the IDO inhibition by TRY and DMT contributed to a more effective tumor-reactive response by the PBMCs.	N,N-dimethyltryptamine	47-50	indoleamine 2,3-dioxygenase 1	Homo sapiens	21-24
23793226-1	2013	BACKGROUND: Ayahuasca, a South American psychotropic plant tea containing the psychedelic 5-HT2A receptor agonist N,N-dimethyltryptamine, has been shown to increase regional cerebral blood flow in prefrontal brain regions after acute administration to humans.	N,N-dimethyltryptamine	114-136	5-hydroxytryptamine receptor 2A	Homo sapiens	90-105
23754498-3	2013	The aim of this study was to identify whether the metabolites originated from the competitive routes of tryptophan metabolism, such as the serotonergic or N, N-dimethyltryptamine (DMT) pathways, have inhibitory effects on recombinant human IDO (rhIDO) activity.	N,N-dimethyltryptamine	155-178	indoleamine 2,3-dioxygenase 1	Homo sapiens	240-243
23754498-3	2013	The aim of this study was to identify whether the metabolites originated from the competitive routes of tryptophan metabolism, such as the serotonergic or N, N-dimethyltryptamine (DMT) pathways, have inhibitory effects on recombinant human IDO (rhIDO) activity.	N,N-dimethyltryptamine	180-183	indoleamine 2,3-dioxygenase 1	Homo sapiens	240-243
22265729-0	2012	Development of the sigma-1 receptor in C-terminals of motoneurons and colocalization with the N,N"-dimethyltryptamine forming enzyme, indole-N-methyl transferase.	N,N-dimethyltryptamine	94-117	sigma non-opioid intracellular receptor 1	Mus musculus	19-35
23461216-11	2012	Recent research showed that endogenous hallucinogen (N,N-dimethyltryptamine) might be a sigma-1 receptor regulator, indicating that sigma-1 receptor is crosely related to psychotomimetic effects.	N,N-dimethyltryptamine	53-75	Adaptor Protein complex 1, sigma subunit	Drosophila melanogaster	88-95
23461216-11	2012	Recent research showed that endogenous hallucinogen (N,N-dimethyltryptamine) might be a sigma-1 receptor regulator, indicating that sigma-1 receptor is crosely related to psychotomimetic effects.	N,N-dimethyltryptamine	53-75	Adaptor Protein complex 1, sigma subunit	Drosophila melanogaster	132-139
22265729-0	2012	Development of the sigma-1 receptor in C-terminals of motoneurons and colocalization with the N,N"-dimethyltryptamine forming enzyme, indole-N-methyl transferase.	N,N-dimethyltryptamine	94-117	indolethylamine N-methyltransferase	Mus musculus	134-161
22265729-5	2012	We found that indole-N-methyl transferase (INMT), an enzyme that converts tryptamine into the sigma-1 ligand dimethyltryptamine (DMT), is also localized to postsynaptic sites of C-terminals in close proximity to the S1R.	N,N-dimethyltryptamine	109-127	indolethylamine N-methyltransferase	Mus musculus	14-41
22265729-5	2012	We found that indole-N-methyl transferase (INMT), an enzyme that converts tryptamine into the sigma-1 ligand dimethyltryptamine (DMT), is also localized to postsynaptic sites of C-terminals in close proximity to the S1R.	N,N-dimethyltryptamine	109-127	indolethylamine N-methyltransferase	Mus musculus	43-47
22265729-5	2012	We found that indole-N-methyl transferase (INMT), an enzyme that converts tryptamine into the sigma-1 ligand dimethyltryptamine (DMT), is also localized to postsynaptic sites of C-terminals in close proximity to the S1R.	N,N-dimethyltryptamine	109-127	sigma non-opioid intracellular receptor 1	Mus musculus	216-219
22265729-5	2012	We found that indole-N-methyl transferase (INMT), an enzyme that converts tryptamine into the sigma-1 ligand dimethyltryptamine (DMT), is also localized to postsynaptic sites of C-terminals in close proximity to the S1R.	N,N-dimethyltryptamine	129-132	indolethylamine N-methyltransferase	Mus musculus	14-41
22265729-5	2012	We found that indole-N-methyl transferase (INMT), an enzyme that converts tryptamine into the sigma-1 ligand dimethyltryptamine (DMT), is also localized to postsynaptic sites of C-terminals in close proximity to the S1R.	N,N-dimethyltryptamine	129-132	indolethylamine N-methyltransferase	Mus musculus	43-47
22265729-5	2012	We found that indole-N-methyl transferase (INMT), an enzyme that converts tryptamine into the sigma-1 ligand dimethyltryptamine (DMT), is also localized to postsynaptic sites of C-terminals in close proximity to the S1R.	N,N-dimethyltryptamine	129-132	sigma non-opioid intracellular receptor 1	Mus musculus	216-219
19756361-0	2009	Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter.	N,N-dimethyltryptamine	0-18	solute carrier family 18 member A2	Homo sapiens	135-156
19756361-7	2009	Our results show that DMT, MIPT, DPT, and DIPT inhibit [(3)H]5-HT transport at the SERT with K ( I ) values of 4.00 +/- 0.70, 8.88 +/- 4.7, 0.594 +/- 0.12, and 2.32 +/- 0.46 microM, respectively.	N,N-dimethyltryptamine	22-25	solute carrier family 6 member 4	Homo sapiens	83-87
19213917-0	2009	The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator.	N,N-dimethyltryptamine	17-39	sigma non-opioid intracellular receptor 1	Mus musculus	63-79
19213917-0	2009	The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator.	N,N-dimethyltryptamine	41-44	sigma non-opioid intracellular receptor 1	Mus musculus	63-79
19213917-3	2009	The sigma-1 receptor pharmacophore includes an alkylamine core, also found in the endogenous compound N,N-dimethyltryptamine (DMT).	N,N-dimethyltryptamine	102-124	sigma non-opioid intracellular receptor 1	Mus musculus	4-20
19213917-3	2009	The sigma-1 receptor pharmacophore includes an alkylamine core, also found in the endogenous compound N,N-dimethyltryptamine (DMT).	N,N-dimethyltryptamine	126-129	sigma non-opioid intracellular receptor 1	Mus musculus	4-20
16095048-1	2005	Bufotenine and N,N-dimethyltryptamine (DMT) are hallucinogenic dimethylated indolethylamines (DMIAs) formed from serotonin and tryptamine by the enzyme indolethylamine N-methyltransferase (INMT) ubiquitously present in non-neural tissues.	N,N-dimethyltryptamine	15-37	indolethylamine N-methyltransferase	Homo sapiens	152-187
16095048-1	2005	Bufotenine and N,N-dimethyltryptamine (DMT) are hallucinogenic dimethylated indolethylamines (DMIAs) formed from serotonin and tryptamine by the enzyme indolethylamine N-methyltransferase (INMT) ubiquitously present in non-neural tissues.	N,N-dimethyltryptamine	15-37	indolethylamine N-methyltransferase	Homo sapiens	189-193
16095048-1	2005	Bufotenine and N,N-dimethyltryptamine (DMT) are hallucinogenic dimethylated indolethylamines (DMIAs) formed from serotonin and tryptamine by the enzyme indolethylamine N-methyltransferase (INMT) ubiquitously present in non-neural tissues.	N,N-dimethyltryptamine	39-42	indolethylamine N-methyltransferase	Homo sapiens	152-187
16095048-1	2005	Bufotenine and N,N-dimethyltryptamine (DMT) are hallucinogenic dimethylated indolethylamines (DMIAs) formed from serotonin and tryptamine by the enzyme indolethylamine N-methyltransferase (INMT) ubiquitously present in non-neural tissues.	N,N-dimethyltryptamine	39-42	indolethylamine N-methyltransferase	Homo sapiens	189-193